

Special Issue

Skin Cancer: Recent Advances for Personalized Treatment

Message from the Guest Editor

Skin cancer affects millions of people worldwide and its incidence is showing a rapid increase every year, making it a public health concern. Both sun exposure and other pathological conditions may interfere with the onset of lesions by also affecting unexposed areas of the skin. Recently, with the advent of a number of sophisticated technologies, we are witnessing an increasingly in-depth analysis of all those factors that can increase our predisposition to the development of melanoma or non-melanoma skin cancer as well as defining those individual characteristics that improve diagnosis and treatment. And, we all know that the early detection of skin cancer gives the greatest chance for a successful cure. In this Special Issue of the *Journal of Personalized Medicine*, manuscripts concerning neoplastic cell-specific markers or molecular profiles aimed at defining novel diagnostic tools promoting personalized therapies are welcome.

Guest Editor

Dr. Elisabetta Palazzo

DermoLab, Department of Surgical, Medical, Dental and Morphological Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy

Deadline for manuscript submissions

closed (25 February 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/76330

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).